The unique mechanism of action of brodalumab allows for blockade of multiple IL-17 isoforms that contribute to psoriatic disease, including IL-17A, IL-17C, and IL-17F; treatment with brodalumab also reduces the expression of IL-23 and IL-12 subunit genes, indicating that brodalumab may reduce inflammatory markers of psoriasis upstream of IL-17 receptor A [2–4]. This evidence concerns the gene IL17A and psoriasis.